✍ Scribed by Edward B. Rubenstein; Douglas E. Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S. Elting; Philip C. Fox; Catherine Cooksley; Stephen T. Sonis
No coin nor oath required. For personal study only.
Oral and gastrointestinal (GI) mucositis can affect up to 100% of patients undergoing high-dose chemotherapy and hematopoietic stem cell transplantation, 80% of patients with malignancies of the head and neck receiving radiotherapy, and a wide range of patients receiving chemotherapy. Alimentary track mucositis increases mortality and morbidity and contributes to rising health care costs. Consequently, the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology assembled an expert panel to evaluate the literature and to create evidence-based guidelines for preventing, evaluating, and treating mucositis.
Thirty-six panelists reviewed literature published between January 1966 and May 2002. An initial meeting in January 2002 produced a preliminary draft of guidelines that was reviewed at a second meeting the same year. Thereafter, a writing committee produced a report on mucositis pathogenesis, epidemiology, and scoring (also included in this issue), as well as clinical practice guidelines.
Panelists created recommendations from higher levels of evidence and suggestions when evidence was of a lower level and there was a consensus regard-
2026
📜 SIMILAR VOLUMES
## Abstract Considerable progress in research and clinical application has been made since the original guidelines for managing mucositis in cancer patients were published in 2004, and the first active drug for the prevention and treatment of this condition has been approved by the United States Fo
## Abstract ## BACKGROUND Mucositis is a common but poorly studied problem among patients with solid tumors. The authors examined the clinical and economic outcomes of oral and gastrointestinal (GI) mucositis among patients receiving myelosuppressive chemotherapy. ## METHODS A retrospective, ran
## The Burdens of Cancer Therapy Clinical and Economic Outcomes of Chemotherapy-Induced Mucositis W e read with great interest the article by Elting et al. describing the clinical and economic outcomes of patients with chemotherapyinduced mucositis. 1 Despite the limitation of a retrospective anal